Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance (SPR) technology and other life sciences testing instruments, has reportedly raised an undisclosed amount in a Pre-Series A financing round led by Jintan Capital. The proceeds will be used to support commercial equipment installation, mass production, marketing and sales, laboratory construction, and new product research and development investments.
Company Background and Milestones
Founded in 2013, Interbio has established itself as a pioneer in the field by commercializing the first China-made SPR product. This achievement underscores the company’s commitment to innovation and its potential to transform the life sciences testing landscape in China and beyond.
Future Outlook
With the support of this Pre-Series A funding, Interbio is poised to accelerate its growth and expand its market presence. The investment will enable the company to enhance its product offerings, scale up production, and strengthen its R&D capabilities, further solidifying its position as a leader in SPR technology.-Fineline Info & Tech
